Management of sickle cell disease;Options thérapeutiques dans la drépanocytose

Revue du Praticien

Volumn 54, Issue 14, 2004, Pages 1557-1564

  De Montalembert, Mariane ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; FOLIC ACID; HAEMOPHILUS VACCINE; HEMOGLOBIN F; HEPATITIS B VACCINE; HYDROXYUREA; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; NITRIC OXIDE; PENICILLIN V; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE;

ACUTE CHEST SYNDROME; ALOPECIA; AMENORRHEA; BLOOD TRANSFUSION; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; EXCHANGE BLOOD TRANSFUSION; FOLLOW UP; HEADACHE; HEMOLYSIS; HLA MATCHING; HUMAN; HYDRATION; HYPOXIA; IRON CHELATION; LIFESTYLE; NAUSEA; NEUTROPENIA; PAIN; PREGNANCY; RASH; REVIEW; SIBLING; SICKLE CELL ANEMIA; STREPTOCOCCUS INFECTION; THROMBOCYTOPENIA;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; HUMANS; HYDROXYUREA; IRON CHELATING AGENTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 4744361497     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Adams RJ, McKie VC, Hsu L et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler untrasonography. N Engl J Med 1998; 339: 5-11.
2. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood 1993; 81: 1109-23.
3. Vichinsky EP, Haberkern CM, Neumayr L et al. A comparison of conservative and aggressive transfusion regimen in the perioperative management of sickle cell disease. N Engl J Med 1995; 333: 206-13.
4. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. N Engl J Med 1988; 319: 1447-52.
5. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38: 30-6.
6. de Montalembert M. Traitement de la drépanocytose par l'hydroxyurée. Hematologie 2002; 8: 28-34.
7. Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Enql J Med 1995; 332: 1317-22.
8. Steinberg MH, Barton F, Castro O et al. Effects of hydroxyurea on mortality and morbidity in adult sickle cell anemia. JAMA 2003; 289: 1645-51.
9. Ferster A, Vermylen C, Cornu G et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996; 88: 1960-4.
10. Ferster A, Tahriri P, Vermylen C et al. Five years of experience with hydroxyurea in children and young adults with sickle cell diease. Blood 2001; 97: 3628-32.
11. de Montalembert M, Bachir D. Traitement de la drépanocytose par l'hydroxyurée. In: Girot R, Béqué P, Galactéros F (eds). I « La drépanocytose ». Paris: John Libbey Eurotext, 2003.
12. Miller ST, Sleeper LA, Pegelow CH et al. Prediction of adverse outcomes in children with sickle cell disease. N Enql J Med 2000; 342: 83-9.
13. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children wih sickle cell disease. Blood 1999; 94: 3022-6.
14. Jeng MR, Rieman MD, Naidu PE et al. Resolution of chronic hepatic sequestration in a patient with homozygous sickle cell disease receiving hydroxyurea. J Pediatr Hematol/Oncol 2003; 25: 257-60.
15. de Montalembert M, Maunoury C, Acar P, Brousse V, Sidi D, Lenoir G. Myocardial ischemia in sickle cell disease. Arch Dis Child 2004; 89: 359-62.
16. de Montalembert M, Bégué P, Bernaudin F, Thuret I, Bachir D, Micheau M. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch Dis Child 1999; 81: 437-9.
17. Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol 2003; 74: 249-53.
18. Saunthararajah Y, Hillery CA, Lavelle D et al. Effects of 5-aza-2′-déoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003; 102: 3865-70.
19. de Franceschi L, Bachir D, Galactéros F et al. Oral magnesium supplements reduce erythrocyte deshydration in patients with sickle cell disease. J Clin Invest 1997; 100: 1847-52.
20. Weiner DL, Hibberd PL, Betit P et al. Preliminary assessment of inhaled nitric oxide for acute vasoocclusive crisis in pediatric patients with sickle cell disease. JAMA 2003; 289: 1136-42.